Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The Power of Rye congress, Mariehamn, June 7–8, 2017 Update on lignans and health – results from the ELIN project Cecilie Kyrø1*, Anne Kirstine Eriksen1, Anne Katrine Bolvig1,2, Natalja Nørskov2, Anne Tjønneland1, Knud Erik Bach Knudsen2 & Anja Olsen1 1 Danish Cancer Society Research Center, Copenhagen, Denmark Department of Animal Science, AU-Foulum, Aarhus University, Tjele, Denmark *[email protected] Project homepage: www.elin-research.dk 2 Lignans are a group of diphenolic compounds found especially in seeds including flaxseeds and sesame seeds, but also whole grains, especially rye, that are a main source especially in Northern Europe. When lignans are ingested, they are converted to enterolactone by the colonic microbiota. Enterolactone has an estrogen-like structure, and may therefore play a role in hormone-related cancers (breast, prostate and colorectum). Especially breast cancer has been studied, and no strong association between enterolactone and the risk of breast cancer has been found. Few studied have investigated the association in relation to prognosis among women with breast cancer and have consistently found enterolactone to be associated with improved prognosis (i.e. lower all-cause mortality, breast cancer-specific mortality). It is biologically plausible that enterolactone also is associated with prognosis of prostate, colorectal cancer as well as other non-communicable diseases, but this remains largely unstudied. The main aim of the ELIN project has been to investigate the role of enterolactone in survival among people with chronic disease (breast cancer, prostate cancer, colorectal cancer, heart disease and type 2 diabetes). In the epidemiological work package of the project, the association between plasma levels of enterolactone has been associated with all-cause mortality and disease-specific mortality. We have followed disease cases (breast cancer, prostate cancer, colorectal cancer, heart disease and type 2 diabetes) from The Danish Diet, Cancer and Health cohort from date of diagnosis and until censoring or end-of-follow-up. During this time, some of the cases have died due to their disease or other causes. Cox proportional hazards models have been used to estimate hazard ratios (HR) with 95% confidence intervals (CI). Plasma concentrations of enterolactone was measured using LC-MS/MS in the following number of cases: - Breast cancer: 1457 cases - Prostate cancer: 1390 cases - Colorectal cancer: 1002 cases - Type 2 diabetes: 1183 cases - Heart disease (myocardial infarction): 1200 cases Preliminary results will be presented at the conference. Funding: Funded by Innovation Fund Denmark (Project ELIN: the effects of enterolignans in chronic disease: 0603-00580B); and Danish Cancer Society.